Founded in 2018 by David Schneider and Florian Hildebrand, Qualifyze, a startup, has just raised twelve million euros in a funding round with the help of venture capital investment. Qualifyze has expertise in data collection related to compliance and supply chain insurance for pharmaceutical manufacturers, who have frequently faced supplier supply failures since 2000. In this context, essential drugs in cancer therapy, for the treatment of epilepsy and Parkinson’s disease, as well as vaccines, become scarce particularly quickly. Special corona drugs in intensive care units have also recently become part of this situation.
Supply bottlenecks and drug shortages gave the founders the idea of acting as helpers in an emergency, because pharmaceutical manufacturers need safety and quality in their supply chains, which they would otherwise have to take on themselves in time-consuming and expensive certifications. Many already existing certificates have become worthless in the meantime.
Qualifyze therefore offers so-called audits via a digital platform, i.e. quality management audits in which the data from suppliers is compiled and evaluated. This collection of data can then be quickly accessed for money by pharmaceutical producers in Germany, for example, because Qualifyze keeps track of the entire supply chain. Supply failures would be more costly than spending money on Qualifyze’s audits.
Audits are legally regulated by standards and specifications that the evaluator (auditor), the young start-up, must follow as a basis for the audits. The auditor, in this case Qualifyze, assesses all drug starting materials on site, mostly in China and India. After all the production conditions have been sufficiently verified, a detailed report is written with data that is compiled on the platform. Thus, data from multiple reports are collected and analyzed using AI. Multiple pharmaceutical producers can then access the audits of a specific supplier.
Audits benefit not only customers and patients due to quality assurance, but also producers in terms of safety and predictability. Many suppliers are afraid of assessments by means of audits, but there are also advantages in this area through confidence building and customer reach extension, explain the founders of Qualifyze. Currently, many manufacturers in the pharmaceutical industry are already part of the audit process optimization customer base. In Germany alone, 300 drugs are already not available.
Source: www.businessinsider.de